Signposts to the Promised Land in Alopecia Areata

Alopecia areata (AA) is an autoimmune disease affecting hair and nails, impacting 329,500-659,000 people in the United States. The Severity of Alopecia Tool (SALT) score, traditionally used to measure disease severity, does not accurately predict the quality of life (QoL) impact, as it overlooks eyebrow and eyelash loss. This study suggests that patient-reported outcomes provide a more accurate depiction of diminished life quality. It also emphasizes the need to redefine disease severity considering emerging therapies and their costs. The study advocates for a shift in clinical practice towards patient perception of disease activity or the Patient Global Impression of Severity scale.